Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31507768 | 0.87 | PIK3CG (0.35) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507867 | 0.86 | PIK3CD (0.31) | PIK3CDPIK3CG | |
| SCHEMBL31507660 | 0.81 | PIK3CG (0.34) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507702 | 0.80 | PIK3CG (0.35) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507713 | 0.80 | PIK3CG (0.34) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507781 | 0.79 | PIK3CG (0.34) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507690 | 0.79 | PIK3CG (0.34) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507776 | 0.79 | PIK3CG (0.35) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507631 | 0.78 | RIPK1 (0.35) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL31507628 | 0.78 | PIK3CG (0.35) | PIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072392-A1 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |